Xvivo Perfusion AB (publ) (XVIVO.ST)
SEK 321.2
(0.63%)
SEK 321.2
(0.63%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 416.91 Million SEK | 40.4% |
| 2022 | 296.95 Million SEK | 57.72% |
| 2021 | 188.27 Million SEK | 41.59% |
| 2020 | 132.97 Million SEK | -18.33% |
| 2019 | 162.81 Million SEK | 19.76% |
| 2018 | 135.95 Million SEK | 19.89% |
| 2017 | 113.39 Million SEK | 10.92% |
| 2016 | 102.23 Million SEK | 20.33% |
| 2015 | 84.96 Million SEK | 32.65% |
| 2014 | 64.04 Million SEK | 18.3% |
| 2013 | 54.13 Million SEK | 374.39% |
| 2012 | 11.41 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 135.1 Million SEK | 53.57% |
| 2024 Q2 | 158.24 Million SEK | 17.13% |
| 2024 Q3 | 147.93 Million SEK | -6.52% |
| 2023 Q4 | 87.97 Million SEK | -18.23% |
| 2023 Q3 | 107.59 Million SEK | -6.81% |
| 2023 Q1 | 104.81 Million SEK | 10.5% |
| 2023 Q2 | 115.46 Million SEK | 10.16% |
| 2023 FY | 416.91 Million SEK | 40.4% |
| 2022 Q1 | 65.22 Million SEK | 3.34% |
| 2022 FY | 296.95 Million SEK | 57.72% |
| 2022 Q4 | 94.85 Million SEK | 36.74% |
| 2022 Q3 | 69.37 Million SEK | 2.76% |
| 2022 Q2 | 67.5 Million SEK | 3.5% |
| 2021 Q2 | 44.54 Million SEK | 4.37% |
| 2021 Q4 | 63.11 Million SEK | 66.38% |
| 2021 Q3 | 37.93 Million SEK | -14.84% |
| 2021 FY | 188.27 Million SEK | 41.59% |
| 2021 Q1 | 42.68 Million SEK | 3.2% |
| 2020 FY | 132.97 Million SEK | -18.33% |
| 2020 Q2 | 23.1 Million SEK | -34.71% |
| 2020 Q3 | 33.13 Million SEK | 43.42% |
| 2020 Q4 | 41.35 Million SEK | 24.82% |
| 2020 Q1 | 35.38 Million SEK | -22.59% |
| 2019 Q1 | 36.91 Million SEK | -11.63% |
| 2019 FY | 162.81 Million SEK | 19.76% |
| 2019 Q3 | 38.54 Million SEK | -7.46% |
| 2019 Q4 | 45.7 Million SEK | 18.59% |
| 2019 Q2 | 41.64 Million SEK | 12.82% |
| 2018 Q1 | 30.11 Million SEK | -5.42% |
| 2018 FY | 135.95 Million SEK | 19.89% |
| 2018 Q4 | 41.77 Million SEK | 34.59% |
| 2018 Q3 | 31.03 Million SEK | -6.03% |
| 2018 Q2 | 33.02 Million SEK | 9.69% |
| 2017 Q2 | 29.21 Million SEK | 7.83% |
| 2017 Q1 | 27.08 Million SEK | -6.23% |
| 2017 FY | 113.39 Million SEK | 10.92% |
| 2017 Q4 | 31.83 Million SEK | 26.04% |
| 2017 Q3 | 25.25 Million SEK | -13.53% |
| 2016 Q2 | 24.85 Million SEK | 2.5% |
| 2016 Q1 | 24.25 Million SEK | -1.51% |
| 2016 FY | 102.23 Million SEK | 20.33% |
| 2016 Q4 | 28.88 Million SEK | 19.19% |
| 2016 Q3 | 24.23 Million SEK | -2.51% |
| 2015 Q2 | 21.73 Million SEK | 11.35% |
| 2015 Q1 | 19.51 Million SEK | -0.46% |
| 2015 FY | 84.96 Million SEK | 32.65% |
| 2015 Q4 | 24.62 Million SEK | 28.99% |
| 2015 Q3 | 19.09 Million SEK | -12.15% |
| 2014 FY | 64.04 Million SEK | 18.3% |
| 2014 Q4 | 19.6 Million SEK | 22.9% |
| 2014 Q2 | 14.61 Million SEK | 5.3% |
| 2014 Q1 | 13.87 Million SEK | -8.91% |
| 2014 Q3 | 15.95 Million SEK | 9.18% |
| 2013 Q4 | 15.23 Million SEK | 13.89% |
| 2013 Q2 | 12.45 Million SEK | -4.81% |
| 2013 FY | 54.13 Million SEK | 374.39% |
| 2013 Q1 | 13.07 Million SEK | 14.61% |
| 2013 Q3 | 13.37 Million SEK | 7.43% |
| 2012 Q4 | 11.41 Million SEK | 0.0% |
| 2012 FY | 11.41 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | -7770.738% |
| ADDvise Group AB (publ) | 300.6 Million SEK | -38.694% |
| ADDvise Group AB (publ) | 300.6 Million SEK | -38.694% |
| Arcoma AB | 11.07 Million SEK | -3665.812% |
| Bactiguard Holding AB (publ) | 139.98 Million SEK | -197.835% |
| BICO Group AB (publ) | 1.83 Billion SEK | 77.225% |
| Boule Diagnostics AB (publ) | 249.71 Million SEK | -66.956% |
| CellaVision AB (publ) | 463.04 Million SEK | 9.962% |
| Clinical Laserthermia Systems AB (publ) | 2.99 Million SEK | -13811.011% |
| Chordate Medical Holding AB (publ) | -28.41 Million SEK | 1567.276% |
| C-Rad AB (publ) | 66.01 Million SEK | -531.543% |
| Duearity AB (publ) | -4.17 Million SEK | 10078.77% |
| Dignitana AB (publ) | 58.97 Million SEK | -606.98% |
| Episurf Medical AB (publ) | -41.8 Million SEK | 1097.4% |
| Getinge AB (publ) | 13.43 Billion SEK | 96.896% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | 930.218% |
| Iconovo AB (publ) | 17.57 Million SEK | -2271.835% |
| Integrum AB (publ) | 690.56 Thousand SEK | -60273.001% |
| Luxbright AB (publ) | -2.79 Million SEK | 15006.381% |
| Mentice AB (publ) | 236.38 Million SEK | -76.373% |
| OssDsign AB (publ) | 83.64 Million SEK | -398.431% |
| Paxman AB (publ) | 12.61 Million SEK | -3204.113% |
| Promimic AB (publ) | 38.51 Million SEK | -982.469% |
| Qlife Holding AB (publ) | -50.75 Million SEK | 921.455% |
| SciBase Holding AB (publ) | 16.03 Million SEK | -2499.694% |
| ScandiDos AB (publ) | 47.55 Million SEK | -776.696% |
| Sectra AB (publ) | 557.55 Million SEK | 25.225% |
| Sedana Medical AB (publ) | 108.98 Million SEK | -282.556% |
| Senzime AB (publ) | 8.33 Million SEK | -4899.556% |
| SpectraCure AB (publ) | -9.22 Million SEK | 4620.362% |
| Stille AB | 132.17 Million SEK | -215.435% |
| Vitrolife AB (publ) | 1.97 Billion SEK | 78.922% |